DENTSPLY SIRONA Inc.
NASDAQ:XRAYMedical - Instruments & Supplies
+$0.19 today
- Market cap
- $1.70B
- Beta
- 0.91
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.14
- Dividend yield
- 6.27%
Volume 5.40M
Average 4.70M
XRAY Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
DENTSPLY SIRONA Inc.NASDAQ: XRAY
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $453M rose 9.7% year over year, ahead of the +4.4% change in trailing-twelve-month cost of revenue. Sequentially, it fell 12.5% from the prior quarter. Over 3 fiscal years it compounded at +0.8% a year.
Context
- Cost of revenue amounted to 50.0% of revenue in FY2025, up 1.6 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +9.7% holds above the trailing-twelve-month pace of +4.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 1.84B USD
- Year-over-year change
- +0.3%
- 4-year CAGR
- -0.6%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.84B | +0.3% |
| FY2024 | 2024-12-31 | 1.84B | -2.3% |
| FY2023 | 2023-12-31 | 1.88B | +4.7% |
| FY2022 | 2022-12-31 | 1.8B | -4.7% |
| FY2021 | 2021-12-31 | 1.88B | — |
Cost of Revenue vs competitors
How XRAY compares with its peers on the latest reported figures
- XRAY's LTM Mar 2026 cost of revenue of $1.88B is the 2nd highest of the 4 companies compared; the peer median is $1.39B.
- Its year-over-year change of +4.4% is the lowest of 4, against a peer median of +8.6%.
- Cost of revenue amounts to 51.1% of revenue for XRAY, versus a peer median of 44.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $9.48B | +5.0% | +1.3% | 69.7% | |
| LTM Mar 2026 | $1.88B | +4.4% | +0.8% | 51.1% | |
| LTM Jun 2026 | $1.39B | +15.8% | +5.1% | 33.5% | |
| LTM Oct 2026 | $1.27B | +8.6% | +4.2% | 44.0% | |
| Peer median (excluding XRAY) | $1.39B | +8.6% | +4.2% | 44.0% | |
Competitors are the stored peer set for XRAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.23B | 3.92B | 3.97B | 3.79B | 3.68B |
| Cost of Revenue | 1.88B | 1.8B | 1.88B | 1.84B | 1.84B |
| Gross Profit | 2.35B | 2.13B | 2.09B | 1.96B | 1.84B |
| Gross Margin | 55.5% | 54.2% | 52.6% | 51.6% | 50.0% |
| Research & Development | 171M | 174M | 184M | 165M | 150M |
| Selling, General & Admin | 1.55B | 1.59B | 1.61B | 1.61B | 1.44B |
| Operating Expenses | 1.74B | 3.06B | 2.17B | 2.84B | 1.59B |
| Depreciation & Amortization | 346M | 328M | 343M | 349M | 352M |
| EBITDA | 952M | (662M) | 249M | (518M) | (46M) |
| EBITDA Margin | 22.5% | -16.9% | 6.3% | -13.7% | -1.3% |
| Operating Income | 608M | (937M) | (85M) | (879M) | 252M |
| Operating Margin | 14.4% | -23.9% | -2.1% | -23.2% | 6.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 61M | 65M | 81M | 69M | 88M |
| Other Income / Expenses | (63M) | (118M) | (90M) | (57M) | (738M) |
| Income Before Tax | 545M | (1.06B) | (175M) | (936M) | (486M) |
| Pre-Tax Margin | 12.9% | -26.9% | -4.4% | -24.7% | -13.2% |
| Income Tax Expense | 134M | (105M) | (43M) | (26M) | 112M |
| Net Income | 411M | (950M) | (132M) | (910M) | (598M) |
| Net Margin | 9.7% | -24.2% | -3.3% | -24.0% | -16.3% |
| EPS (Basic) | 1.88 | (4.41) | (0.62) | (4.48) | (3.00) |
| EPS (Diluted) | 1.87 | (4.41) | (0.62) | (4.48) | (3.00) |
| Weighted Avg Shares | 218.4M | 215.5M | 212M | 203.2M | 199.4M |
| Weighted Avg Shares (Diluted) | 220.2M | 215.5M | 212M | 203.2M | 199.4M |
DENTSPLY SIRONA Inc.
NASDAQ:XRAY
Intrinsic Alpha fair value
Locked
Current Price
$8.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.